Aachen, Germany, 1st March 2023 – Janneke van der Kamp has right this moment assumed her position as the brand new Chief Industrial Officer (CCO) of Grünenthal. She joins Grünenthal’s govt board and is liable for the complete World Industrial Organisation.
As CCO of Grünenthal, Janneke van der Kamp’s focus will probably be to additional strengthen Grünenthal’s business actions and develop the corporate’s key manufacturers, particularly Qutenza® (8% capsaicin topical system) within the US. Janneke van der Kamp may even be liable for the launch preparations of Grünenthal’s promising pipeline asset, resiniferatoxin (RTX), for treating sufferers with average to extreme ache related to knee osteoarthritis. An ongoing medical Part III programme throughout websites in Europe, the US, Latin America, South Africa, and Japan goals to allow advertising and marketing approval for the investigational drugs.
Janneke van der Kamp
Janneke van der Kamp joins Grünenthal at an thrilling level within the firm’s transformation journey. Since 2017, Grünenthal’s profitability, measured by adjusted EBITDA, has greater than tripled. Throughout this time, Grünenthal closed profitable acquisitions with a complete anticipated deal worth of greater than € 2 billion. Moreover, the corporate expanded its geographical footprint, with its affiliate Averitas Pharma, Inc., commercialising Qutenza® (8% capsaicin topical system) within the US.
“I’m thrilled to affix Grünenthal at such an thrilling time and work with colleagues the world over on our imaginative and prescient of a world freed from ache,” says Janneke van der Kamp. “I’m assured that collectively we’ll attain much more sufferers with our medicines and be optimally ready for the launch of our late pipeline belongings.”
Janneke van der Kamp joins Grünenthal from Novartis, the place she most just lately served as Head of Pharma Area Europe. The Dutch native brings broad expertise within the pharmaceutical trade from a number of roles, together with Basic Supervisor, World Neurosciences Franchise Head, and World Head of Product and Portfolio Technique for the complete Novartis Pharma portfolio. She has huge experience in launching and rising key manufacturers throughout a number of illness areas. Janneke van der Kamp is a studied chemist and holds an MBA from INSEAD.
Janneke van der Kamp succeeds Mark Fladrich, who will retire from Grünenthal after greater than 5 years with the corporate. Throughout this time, he reworked Grünenthal’s business organisation, contributing to the corporate’s sturdy revenue progress all through his tenure.
Janneke van der Kamp’s Bio may be learn right here: Management at Grünenthal | About us | Grünenthal (grunenthal.com)
Grünenthal is a world chief in ache administration and associated illnesses. As a science-based, totally built-in pharmaceutical firm, we have now an extended observe report of bringing revolutionary therapies and state-of-the-art applied sciences to sufferers worldwide. Our objective is to vary lives for the higher – and innovation is our ardour. We’re focusing all of our actions and efforts on working in the direction of our imaginative and prescient of a world freed from ache.
Grünenthal is headquartered in Aachen, Germany, and has associates in 28 international locations throughout Europe, Latin America and the US. Our merchandise can be found in additional than 100 international locations. In 2021, Grünenthal employed round 4,500 folks and achieved gross sales of € 1.5 bn.
Extra data: www.grunenthal.com
Click on right here for our Grünenthal Report 2021/2022: https://options.grunenthal.com/gruenenthal-annual-report-2021-22/index.html
Observe us on:
LinkedIn: Grunenthal Group
For additional data, please contact
Head of Exterior Communication
Telephone: +49 241 569-3269
E-mail: [email protected]
Head World Industrial Communication
E-mail: [email protected]